Search Results

Renibus Therapeutics®, a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, announced a transition in its leadership structure.

Renibus Therapeutics® (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced that Frank Stonebanks, Renibus’ Co-CEO, and Bhupinder Singh, MD, Renibus’ CMO, will participate in a fireside chat on February 29, 2024, at 3:25 pm ET at the Evercore ISI 2024 Emerging Biotech Conference.

Renibus Therapeutics® (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference, being held in a virtual format, April 8-11, 2024.

Renibus Therapeutics® (“Renibus”) today announced that Frank Stonebanks, Renibus’ Co-CEO, will present a company overview on February 14, 2024, at 2:40 pm ET at the Oppenheimer 34th Annual Healthcare Conference, taking place virtually from February 13-14, 2024.

Renibus Therapeutics, Inc., (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, today announced participation in the following upcoming investor conferences.

Renibus Therapeutics® today announced its participation at two prestigious medical conferences: the American Association for Thoracic Surgery (AATS) 104th Annual Meeting and the Society of Cardiovascular Anesthesiologists (SCA) 46th Annual Meeting, both taking place in Toronto, Canada, April 27-30, 2024.

Renibus Therapeutics today announced an oral presentation on RBT-1 at the prestigious, invitation only, European Association for Cardio-Thoracic Surgery (EACTS) 2 nd Innovation Summit, taking place in Paris, France, April 18-20, 2024.

Renibus Therapeutics, Inc. today announced the close of an extension to its Series B financing round, bringing the total amount raised to $72 million.

Renibus Therapeutics today announced that Frank Stonebanks , Renibus’ Co-CEO, will present a company overview at the Oppenheimer 33rd Annual Healthcare Conference, taking place virtually from March 13-15 , 2023.

Renibus Therapeutics® (“Renibus”), a clinical-stage biotech company focusing on the prevention and treatment of cardio-renal diseases, today announced that company management will participate in the 22nd Annual Needham Virtual Healthcare Conference, taking place virtually from April 17-20, 2023.